DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dynacin (Minocycline Hydrochloride) - Summary

 
 



DYNACIN SUMMARY

DYNACIN® (MINOCYCLINE HCl TABLETS, USP)

Minocycline hydrochloride, a semisynthetic derivative of tetracycline, is 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.

Minocycline hydrochloride tablets are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:

  •  Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae.
  •  Respiratory tract infections caused by Mycoplasma pneumoniae.
  •  Lymphogranuloma venereum caused by Chlamydia trachomatis.
  •  Psittacosis (Ornithosis) due to Chlamydia psittaci.
  •  Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunoflourescence.
  •  Inclusion conjunctivitis caused by Chlamydia trachomatis.
  •  Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis.
  •  Relapsing fever due to Borrelia recurrentis.
  •  Chancroid caused by Haemophilus ducreyi.
  •  Plague due to Yersinia pestis.
  •  Tularemia due to Francisella tularensis.
  •  Cholera caused by Vibrio cholerae.
  •  Campylobacter fetus infections caused by Campylobacter fetus.
  •  Brucellosis due to Brucella species (in conjunction with streptomycin).
  •  Bartonellosis due to Bartonella bacilliformis.
  •  Granuloma inguinale caused by Calymmatobacterium granulomatis.

Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:

  •   Escherichia coli.
  •   Enterobacter aerogenes.
  •   Shigella species.
  •   Acinetobacter species.
  •  Respiratory tract infections caused by Haemophilus influenzae.
  •  Respiratory tract and urinary tract infections caused by Klebsiella species.

Minocycline hydrochloride tablets are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

  •  Upper respiratory tract infections caused by Streptococcus pneumoniae.
  •  Skin and skin structure infections caused by Staphylococcus aureus.
  •  (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.)

When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections:

  •  Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections.
  •  Infections in women caused by Neisseria gonorrhoeae.
  •  Syphilis caused by Treponema pallidum subspecies pallidum.
  •  Yaws caused by Treponema pallidum subspecies pertenue.
  •  Listeriosis due to Listeria monocytogenes.
  •  Anthrax due to Bacillus anthracis.
  •  Vincent's infection caused by Fusobacterium fusiforme.
  •  Actinomycosis caused by Actinomyces israelii.
  •  Infections caused by Clostridium species.

In acute intestinal amebiasis, minocycline may be useful adjunct to amebicides.

In severe acne, minocycline may be useful adjunctive therapy.

Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate the meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carrier, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high.

Oral minocycline is not indicated for the treatment of meningococcal infection.

Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of, minocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.


See all Dynacin indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Dynacin (Minocycline)

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. [2012]
The onset and early course of schizophrenia is associated with subtle loss of grey matter which may be responsible for the evolution and persistence of symptoms such as apathy, emotional blunting, and social withdrawal...

Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. [2012]
Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline... Although this study does not establish the efficacy of minocycline in spinal cord injury the findings are encouraging and warrant further investigation in a multi-centre phase III trial.

Minocycline-EDTA lock solution prevents catheter-related bacteremia in hemodialysis. [2011.10]
There is growing concern about the development of antibacterial resistance with the use of antibiotics in catheter lock solutions...

Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. [2011.09.20]
OBJECTIVE: We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment... CONCLUSION: Minocycline was safe and well-tolerated in individuals with HIV-associated cognitive impairment, but cognitive improvement was not observed. Classification of evidence. This interventional study provides Class II evidence for the safety, tolerability, and efficacy of minocycline for the treatment of HIV-associated cognitive impairment.

Clinical and biochemical efficacy of minocycline in nonsurgical periodontal therapy: a randomized controlled pilot study. [2011.06]
The present study evaluated the effects of systemic minocycline on clinical and biochemical parameters of chronic periodontitis, which is a common inflammatory disorder of the periodontium initiated by the presence of bacteria in the gingival sulcus...

more studies >>

Clinical Trials Related to Dynacin (Minocycline)

Pilot Study of Minocycline in Huntington's Disease [Active, not recruiting]
This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy [Recruiting]
The goal of this clinical research study is to learn if minocycline can reduce the side effects reported by patients with non small cell lung cancer (NSCLC) who are receiving chemoradiation therapy. In this study, minocycline will be compared to a placebo.

Minocycline is an antibiotic that may help to reduce side effects of chemoradiation therapy.

A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer [Not yet recruiting]
The goal of this clinical research study is to compare armodafinil and minocycline when given alone or in combination to learn which is better for controlling side effects of chemoradiation treatment for esophageal cancer (such as fatigue, pain, disturbed sleep, lack of appetite, and drowsiness).

Armodafinil is designed to prevent excessive sleepiness.

Minocycline is an antibiotic, which may help to reduce multiple symptoms.

In this study, you may receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Minocycline Study in Pancreatic Cancer Patients [Not yet recruiting]
The goal of this clinical research study is to learn if minocycline can reduce the side effects of chemotherapy in patients with pancreatic cancer. In this study, minocycline will be compared to a placebo.

Minocycline is an antibiotic that may help to reduce side effects of chemotherapy.

A placebo is not a drug. It looks like the study drug, but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil [Recruiting]
The goal of this clinical research study is to compare armodafinil and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.

more trials >>


Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014